TY - JOUR
T1 - A validation study of the remotely administered Montreal cognitive assessment tool in the elderly Japanese population
AU - Iiboshi, Kiyoko
AU - Yoshida, Kazunari
AU - Yamaoka, Yoshitaka
AU - Eguchi, Yoko
AU - Sato, Daisuke
AU - Kishimoto, Megumi
AU - Funaki, Kei
AU - Mimura, Masaru
AU - Kishimoto, Taishiro
N1 - Funding Information:
This research was supported by the Japan Agency for Medical Research and Development (AMED) under grant number 161k1010023h0001. AMED did not have any influence on designing the study, conducting the study, or analyzing the results.
Funding Information:
K.Y. has received article fees from Sumitomo Dainippon Pharma, fellowship grants from the Japan Research Foundation for Clinical Pharmacology, and consultant fees from Bracket and VeraSci within the past 3 years. Y.E. has received grants from Mitsubishi Foundation, Daiwa Securities Health Foundation, and Okawa Foundation within the past 3 years. M.M. has received grants and/or speaker’s honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, No-vartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past 3 years. T.K. has received consultant fees from Dainippon Sumitomo, Novartis, and Otsuka, and speaker’s honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka, and Pfizer within the past 3 years. He also received royalties from UpToDate. The other authors have nothing to disclose.
Publisher Copyright:
© MARY ANN LIEBERT, INC.
PY - 2020/7
Y1 - 2020/7
N2 - Background: In an aging society, neuropsychological testing using video teleconferencing (VTC) is increasingly important. Despite the potential benefit of a VTC-administered Montreal Cognitive Assessment Tool (MoCA) to detect cognitive decline, only a limited number of studies have investigated this tool's reliability. Therefore, we aimed to evaluate the reliability of VTC-administered MoCA compared with face-to-face (FTF)-administered MoCA among elderly Japanese participants. Moreover, we examined participants' satisfaction with VTC-administered MoCA. Methods: Participants ‡60 years of age with and without cognitive impairment (i.e., those with mild cognitive impairment [MCI], those with dementia, and healthy controls [HC]) were assessed with VTC- and FTF-administered MoCA at an interval of >2 weeks and <3 months. The order effect (VTC first vs. FTF first) and time effect (first vs. second testing session), as well as several covariates such as age and years of education were controlled. Intraclass correlation coefficients (ICCs) were calculated using a mixed-effects model to assess the agreement between the two (VTC- vs. FTF-administered) groups. Participants' satisfaction with VTC-administered MoCA was examined using a Likert scale asking seven questions. Results: We included 73 participants in the study (36 men; age, 76.3 - 7.5 years). The ICC for the MoCA total score was high in the entire sample (0.85), whereas ICCs were moderate to high for the subgroups (MCI: 0.82, dementia: 0.82, and HC: 0.53). Furthermore, we found good overall participant satisfaction with VTC-administered MoCA. Discussion: VTC-administered MoCA appears viable as an alternative to FTF-administered MoCA, although further replication studies with larger sample sizes are needed.
AB - Background: In an aging society, neuropsychological testing using video teleconferencing (VTC) is increasingly important. Despite the potential benefit of a VTC-administered Montreal Cognitive Assessment Tool (MoCA) to detect cognitive decline, only a limited number of studies have investigated this tool's reliability. Therefore, we aimed to evaluate the reliability of VTC-administered MoCA compared with face-to-face (FTF)-administered MoCA among elderly Japanese participants. Moreover, we examined participants' satisfaction with VTC-administered MoCA. Methods: Participants ‡60 years of age with and without cognitive impairment (i.e., those with mild cognitive impairment [MCI], those with dementia, and healthy controls [HC]) were assessed with VTC- and FTF-administered MoCA at an interval of >2 weeks and <3 months. The order effect (VTC first vs. FTF first) and time effect (first vs. second testing session), as well as several covariates such as age and years of education were controlled. Intraclass correlation coefficients (ICCs) were calculated using a mixed-effects model to assess the agreement between the two (VTC- vs. FTF-administered) groups. Participants' satisfaction with VTC-administered MoCA was examined using a Likert scale asking seven questions. Results: We included 73 participants in the study (36 men; age, 76.3 - 7.5 years). The ICC for the MoCA total score was high in the entire sample (0.85), whereas ICCs were moderate to high for the subgroups (MCI: 0.82, dementia: 0.82, and HC: 0.53). Furthermore, we found good overall participant satisfaction with VTC-administered MoCA. Discussion: VTC-administered MoCA appears viable as an alternative to FTF-administered MoCA, although further replication studies with larger sample sizes are needed.
KW - Alzheimer's disease
KW - Mild cognitive impairment
KW - MoCA
KW - Neuropsychological tests
KW - Telepsychiatry
UR - http://www.scopus.com/inward/record.url?scp=85088486303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088486303&partnerID=8YFLogxK
U2 - 10.1089/tmj.2019.0134
DO - 10.1089/tmj.2019.0134
M3 - Article
C2 - 31746697
AN - SCOPUS:85088486303
SN - 1530-5627
VL - 26
SP - 920
EP - 928
JO - Telemedicine Journal and e-Health
JF - Telemedicine Journal and e-Health
IS - 7
ER -